External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home EHA 2025
Roche and Genentech at

EHA 2025

June 12 - June 15
Milan, Italy / Virtual (Hybrid)
eha.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
02:00 PM
Duration 60mins Milan, Italy
2-year efficacy and safety in patients with paroxysmal nocturnal hemoglobinuria (PNH) who self-administered crovalimab▼ in the Phase III randomized COMMODORE 2 trial
Alexander Röth, Guangsheng He, Andres Brodsky, Chatree Chai-Adisaksopha, Teresita E. Dumagay, Roberta Demichelis Gómez, Martin Höglund, Richard J. Kelly, Je-Hwan Lee, Jun-ichi Nishimura, Naoshi Obara, Antonio Risitano, Anna Gaya, Anita Appius, Hannah Staunton, Sasha Sreckovic, Sammy Chebon, Simon Buatois, Bing Han
Haematology - Oncology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:00 AM
Duration 90mins Milan, Italy
Bispecific antibodies: Advances in the treatment of relapsed/refractory follicular lymphoma
Sehn L, Scholz C, Falchi L, Iacoboni G
Haematology - Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:30 PM
Duration 60mins Milan, Italy
Mosunetuzumab▼ demonstrates durable clinical benefit in patients (pts) with complete response (CR) and high-risk relapsed/refractory (R/R) follicular lymphoma (FL)
Cheah CY, Barlett NL, Matasar M, Schuster SJ, Assouline S, Sehn LH, Kuruvilla J, Giri P, Shadman M, Ku M, Hess G, Gregory GP, Kim W, Wei MC, Yin S, Sit J, Tracy S, Kwan A, Penuel E, Budde EL
Haematology - Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:00 AM
Duration 90mins Milan, Italy
Building better outcomes for patients with diffuse large B-cell lymphoma (DLBCL): Today's treatments and tomorrow's innovations
Burke J, Gregory G, Zhao W, Dietrich S
Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:45 AM
Duration 15mins Allianz MiCo Milano Convention Centre
Polatuzumab vedotin▼, rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results from the randomized phase III POLARGO trial
Matasar M, Li Z, Vassilakopoulos T, Sancho JM, Viardot A, McMillan, A, Dal MS, Pereira J, Kim JS, Qiu L, Batlevi CL, Ibrahim R, Hernandez J, McCall B, Jiang Y, Yan M, Harris W, Musick L, Haioun C
Haematology - Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:00 PM
Duration 15mins Allianz MiCo Milano Convention Centre
MorningSun: open-label phase II trial of the efficacy and safety of subcutaneous mosunetuzumab▼ (Mosun SC) as frontline (1L) treatment in symptomatic patients with marginal zone lymphoma (MZL)
Burke JM, Tun AM, Villasboas J, Budde LE, Gandhi M, Graff T, Jani P, Biondo JML, Wu M, Farighi R, Mun Y, Lin T, Munoz J, Flinn I
Haematology - Oncology | Non Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:30 PM
Duration 60mins Milan, Italy
Glofitamab▼ plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of STARGLO
Gregory GP, Ku M, Hertzberg M, Fox CP, Herbaux C, Huang H-Q, Yoon DH, Kim WS, Zhang H, Abdulhaq H, Townsend W, Mulvihill E, Ta R, Huang H, Kallemeijn MJ, Belousov A, Bottos A, Lundberg L, Abramson JS
Haematology - Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Milan, Italy
Impact of tumor burden and prior venetoclax treatment on mosunetuzumab▼-mediated tumour control in relapsed/refractory CLL
Jin HY, Barrett K, Schroeder A, Ho H, Breton V, Penuel E, Kesavan M, Breuleux M, Sugidono M, Opat S, Tausch E
Haematology - Oncology | Chronic Lymphocytic Leukemia

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Milan, Italy
Fixed-duration subcutaneous mosunetuzumab▼ demonstrates clinically relevant efficacy in patients with relapsed/refractory follicular lymphoma with high-risk features: pivotal phase II study update
Hess G, Sehn LH, Budde EL, Assouline S, Giri P, Kuruvilla J, Schuster SJ, Yoon SS, Fay K, Dreyling M, Guitierrez NC, Cybulski E, Sabalvaro F, Penuel E, Tracy S, Kuruvilla D, Chen J, Wiebking V, Wei MC, Bartlett NL
Haematology - Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.